Dynamic Technology Lab Private Ltd boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 42.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,346 shares of the company's stock after acquiring an additional 5,795 shares during the quarter. Dynamic Technology Lab Private Ltd's holdings in Novo Nordisk A/S were worth $1,664,000 at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in NVO. GQG Partners LLC increased its holdings in Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after purchasing an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $404,910,000. Loomis Sayles & Co. L P boosted its position in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Novo Nordisk A/S by 59.8% during the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after purchasing an additional 1,602,549 shares during the period. Finally, Sustainable Growth Advisers LP lifted its stake in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock valued at $459,416,000 after buying an additional 1,021,498 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.
Wall Street Analysts Forecast Growth
NVO has been the subject of several recent analyst reports. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. BMO Capital Markets reduced their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $145.25.
Get Our Latest Stock Analysis on Novo Nordisk A/S
Novo Nordisk A/S Stock Down 2.4 %
Novo Nordisk A/S stock traded down $1.51 during mid-day trading on Wednesday, reaching $60.09. The company's stock had a trading volume of 4,719,218 shares, compared to its average volume of 5,696,344. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a 12 month low of $59.01 and a 12 month high of $148.15. The business's 50 day simple moving average is $79.45 and its 200 day simple moving average is $95.04. The company has a market capitalization of $269.67 billion, a price-to-earnings ratio of 18.27, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.
Novo Nordisk A/S Increases Dividend
The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a dividend of $0.7874 per share. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is 49.54%.
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Further Reading
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
